Related Experiment Videos
[Low-molecular weight heparins. Prospects in 1985]
Annales De Medecine Interne
|January 1, 1986
Summary
Low molecular weight heparin (LMW-Hep) offers an effective antithrombotic therapy with a longer biological effect, reducing the need for multiple injections. Monitoring anti-Xa activity is crucial for safe and effective LMW-Hep dosing.
Area of Science:
- Pharmacology and Thrombosis Research
- Biochemistry of Coagulation
Context:
- Low molecular weight heparin (LMW-Hep) interacts with the coagulation system, modulating anti-Xa and anticoagulation activities.
- LMW-Hep exhibits antithrombotic effects comparable to unfractionated heparin in animal models.
- The prolonged biological half-life of LMW-Hep allows for subcutaneous administration and reduced dosing frequency for preventing post-operative thrombosis.
Purpose:
- To highlight the need for standardized methods to assess LMW-Hep efficacy.
- To emphasize the importance of biological surveys for monitoring LMW-Hep therapy.
- To establish anti-Xa activity as the key metric for LMW-Hep evaluation due to the insensitivity of conventional tests.
Summary:
- Current therapeutic strategies for thrombosis are being reassessed with LMW-Hep, showing increased efficacy.
- Posology of LMW-Hep is increasingly expressed in milligrams, moving away from older measurement methods.
- High doses of LMW-Hep can lead to hemorrhagic complications in surgical patients, necessitating careful biological monitoring.
Impact:
- LMW-Hep represents a novel concept in antithrombotic therapy, characterized by low anticoagulant action.
- Accurate monitoring of anti-Xa activity is essential for optimizing LMW-Hep treatment and preventing adverse events.
- Further research and standardization are needed to fully realize the therapeutic potential of LMW-Hep.